Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module A-D (L269121)
ACPE Numbers: Various – see listing below
Content Release Date: September 09, 2026
Expiration Dates: September 07, 2027
Activity Type: Application-based
CE Credits: 16 contact hours (ACPE and BPS)
Activity Fee: $315 (ASHP member); $455 (non-member)
The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The Home Study Syllabus is released as a single 16-hour package (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.
Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.
Accreditation
 |
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. |
 |
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. |
Target Audience
These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:
- Adult Acute Leukemia
- Adult Sarcoma
- Breast Cancer
- Chronic Leukemia
- Gastroesophageal Cancers
- Hematopoietic Cell Transplantation
- Lung Cancer
- Ovarian Cancer
- Pediatric Malignancy
- Statistics
- Urothelial Carcinoma
Recertification Credit
Board-certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ASHP and ACCP are approved by BPS as providers for the recertification of BCOP.
|
Learning Activity |
ACPE Number |
Contact Hours (ACPE & BPS) |
Assessment Pass Point |
|
Module A: Acute Leukemia, Chronic Leukemia, and Graft-versus-Host Disease |
0204-9999-26-937-H01-P |
4.5 |
76% |
| Module B: Urothelial Carcinoma, Ovarian Cancer, and Adult Sarcoma |
0204-9999-26-938-H01-P |
4.0 |
80% |
| Module C: Lung Cancer, Pediatric Malignancy, and Breast Cancer |
0204-9999-26-939-H01-P |
4.5 |
77% |
| Module D: Statistics and Cancers of the GI tract |
0204-9999-26-940-H01-P |
3.0 |
78% |
Articles and Learning Objectives
Module A: Acute Leukemia, Chronic Leukemia, and Graft-versus-Host Disease
ACPE # 0204-9999-26-937-H01-P
Jabbour EJ, Kantarjian HM, Goekbuget N, et al. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024;14(1):203
Learning Objectives:
- Select an appropriate frontline chemotherapy backbone for adults with Ph-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) based on age, fitness, comorbidities, and functional status.
- Compare common frontline ALL regimens to identify major toxicity drivers and practical treatment implications across phases of care.
Sharman JP, Munir T, Grosicki S, et al. Phase III trial of pirtobrutinib versus idelalisib/rituximab or bendamustine/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol. 2025;43(22):2538-49. doi: 10.1200/JCO-25-00166.
Learning Objectives:
- Describe the BRUIN CLL-321 trial of pirtobrutinib for the treatment of chronic lymphocytic leukemia after the receipt of a covalent Bruton tyrosine kinase inhibitor.
- Develop recommendations for the use of pirtobrutinib for the treatment of chronic lymphocytic leukemia after the receipt of a covalent Bruton tyrosine kinase inhibitor as reported in the BRUIN CLL-321 trial.
Wolff D, Cutler C, Lee SJ, et al. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024;391(11):1002-1014.
Learning Objectives:
- Describe the study of axatilimab for refractory chronic graft-versus-host disease in patients following allogeneic hematopoietic cell transplantation.
- Develop recommendations for the use of axatilimab in patients with refractory chronic graft-versus-host disease.
- Select appropriate patients to receive axatilimab for refractory chronic graft-versus-host disease based on the results of the AGAVE-201 trial.
Module B: Urothelial Carcinoma, Ovarian Cancer, and Adult Sarcoma
ACPE # 0204-9999-26-938-H01-P
Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898-912. https://doi.org/10.1056/NEJMoa2210140
Learning Objectives:
- Describe the design and key efficacy outcomes of the DeFi trial evaluating nirogacestat in adults with progressing desmoid tumors.
- Apply DeFi trial efficacy and patient-reported outcome data to clinical decision-making for patients with progressing desmoid tumors.
- Develop monitoring and management strategies for toxicities associated with nirogacestat, including gastrointestinal effects, electrolyte abnormalities, and ovarian dysfunction.
Apolo AB, Ballman KV, Sonpavde G, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45-55.
Learning Objectives:
- Describe the study by Apolo and colleagues of adjuvant pembrolizumab vs. observation for muscle-invasive urothelial carcinoma.
- Develop recommendations for the use of adjuvant pembrolizumab in patients with newly diagnosed muscle-invasive bladder cancer.
- Select appropriate patients to receive adjuvant pembrolizumab based on the results of the AMBASSADOR trial by Apolo et al.
Susana N. Banerjee et al.Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol 43, 2782-2792(2025).
Learning Objectives:
- Describe the study of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer.
- Develop recommendations for the use of avutometinib with defactinib in patients with recurrent low-grade serous ovarian cancer.
- Select appropriate patient to receive avutometinib with defactinib according to the results of the RAMP 201 study.
Module C: Lung Cancer, Pediatric Malignancy, and Breast Cancer
ACPE # 0204-9999-26-939-H01-P
Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024; 43(1): 75-84.
Learning Objectives:
- Describe the study of revumenib for relapsed or refractory acute leukemias.
- Develop recommendations for the use of revumenib in patients with relapsed or refractory acute leukemias.
- Select appropriate patients to receive revumenib therapy based on the results of the study by Issa, et al.
Loibl S, Park YH, Shao Z, et al; for the DESTINY-Breast05 Trial Investigators. Trastuzumab deruxtecan in residual HER2-positive early breast cancer—correction. N Engl J Med. 2026;394(13):1352.
Learning Objectives:
- Describe the DESTINY-Breast05 study of trastuzumab deruxtecan for the adjuvant treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer at high risk for recurrence.
- Develop recommendations for the use of trastuzumab deruxtecan in patients with early stage HER2-positive breast cancer.
- Select appropriate patients to receive trastuzumab deruxtecan based on the results of the DESTINY-Breast05 trial.
Su PL, Furuya N, Asrar A, et al. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematology & Oncology. 2025;18:35;1-30.
Learning Objectives:
- Describe the therapeutic strategies available for patients with advanced non-small cell lung cancer.
- Develop recommendations for the treatment of advanced non-small cell lung cancer based on the results of the landmark trials described within the review.
- Select appropriate patients to receive targeted therapy, immunotherapy, and cytotoxic therapy based on the results of the landmark trials presented within the review.
Module D: Statistics and Cancers of the GI tract
ACPE # 0204-9999-26-940-H01-P
-
Paul J, Barari M. Meta‐analysis and traditional systematic literature reviews—what, why, when, where, and how? Psychol Mark. 2022;39(6):1099-1115. https://psycnet.apa.org/doi/10.1002/mar.21657
-
Ji X, Wang G, Pan D, Xu S, Lei X. Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):173.
Learning Objectives:
- Explain the differences between a systematic review and meta-analysis.
- Critique the methodology used for a systematic review or meta-analysis.
- Evaluate the results of a systematic review or meta-analysis.
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217-230.
Learning Objectives:
- Describe the MATTERHORN trial comparing durvalumab and FLOT (5-fluorouracil/leucovorin, oxaliplatin, docetaxel) to FLOT alone as perioperative therapy for gastric and gastroesophageal junction cancers.
- Develop recommendations for the use of durvalumab and FLOT as perioperative therapy for gastric and gastroesophageal junction cancers based on the MATTERHORN trial.
- Select appropriate patients to receive durvalumab and FLOT based on the MATTERHORN trial.
Faculty
John Bossaer, PharmD, BCOP
Professor
ETSU Bill Gatton College of Pharmacy
Johnson City, Tennessee
Courtney C. Cavalieri, PharmD, BCOP
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
*Karen M. Fancher, PharmD, BCOP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania
*Lauren Ice, PharmD, BCOP, BCPS
Pharmacist Supervisor
Corewell Health
Grand Rapids, Michigan
Alexis R. Jones, PharmD, BCOP, CPP
Gynecologic Oncology Clinical Pharmacist
University of North Carolina Medical Center
Chapel Hill, North Carolina
Elyse A. MacDonald, PharmD, MS, BCPS, FASHP
Director, Investigational Drug Service
Stanford Health Care
Palo Alto, California
Janelle Mann, PharmD, BCOP
Pharmacy Manager/Clinical Pharmacist Specialist - Outpatient Oncology
Barnes-Jewish Hospital/Washington University School of Medicine
St. Louis, Missouri
Colleen McCabe, PharmD, BCOP
Clinical Pharmacy Specialist, Oncology
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
*Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan
Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania
*Christine M. Walko, PharmD, BCOP, FCCP
Senior Member, Individualized Cancer Management
Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida
Jennifer Young, PharmD, BCOP
Clinical Pharmacy Specialist
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio
*Content Matter Experts
Reviewers
Angela T. Cassano, PharmD, BCPS, FASHP
Sue Dombrowski, MS, RPh
Field Testers
Ghaida Aldajani, PharmD, BCPS, BCOP
Diana Alex, PharmD, BCOP
Usama Mudhar Abdulridha Algamli, RPh, BCOP, BCPP
Shoni Alsup, PharmD, BCOP
Hui Qin Ang, BSPharm (Hons), BCIDP, BCPS, BCOP
Justin Arnall, PharmD, BCOP, FCCP
Kimberly Aronoff, BSPharm, PharmD, BCOP
Arwa Bader, PharmD, BCOP
Yong jun Bae, PharmD
Allison Bass, PharmD, BCOP
Mollie Beck, PharmD, BCOP
Charles Bockelman, PharmD, BCOP
Janet Bramell, PharmD, BCOP, BCPS
Kelly Brunk, PharmD, MBA, BCOP
Lauren Campanella, PharmD, BCOP
Leslie Carlin, PharmD, BCOP
Zhi Yao Chan, MClinPharm, BCOP
Anil Chava, PhD,MS,RPh,BCOP
Jill Comeau, PharmD, BCOP
Allison Cone, PharmD, BCOP, BCPS
Alexandra Cox, PharmD, BCOP
Samantha Coykendall, PharmD, BCOP
Nicole Davis, PharmD, BCPS, BCOP
Heba Elhor, BCOP, BCPS
Bryna Ewachiw, PharmD, BCOP
Zhou Fang, PharmD, BCOP
Sara Fleszar, Pharm D, BCOP
Catherine Godfrey, PharmD, BCOP
Rene Gonzalez, PharmD, BCOP, BCPS
Aisha Grant, PharmD, BCOP, BCPS
Victoria Grusauskas, PharmD, BCOP
Timothy Hamer, PharmD
Christine Hansen, PharmD, BCOP
Nathan Heitz, PharmD, BCOP
Katherine Hill, PharmD, BCOP
Mikala Hillis, PharmD, MMHC, BCOP
Wei Ho, MClinpharm, BCOP
Christina Hoppe, PharmD, MBA, BCOP
Isabel Houlzet, PharmD, BCOP
Elizabeth Jackson, PharmD, BCOP
Megan James, PharmD
Mark Jao, PharmD, BCOP
Angela Johnston Willis, PharmD, BCOP
Jocelyn Joseph, PharmD, BCOP
Kori Kallenborn, PharmD, BCOP
Riley Karpen, PharmD, MBA, BCOP
Emily Ketchum, PharmD, BCOP
Yuri Kim, PharmD, BCOP
Leigh Kipley, PharmD, BCOP
Sara Kreshpanji, PharmD, BCOP
Kim Chiu Lam, BPharm, BCGP, BCOP
Dennis Lee, PharmD, BCOP, BCPS
John Lee, PharmD, BCOP
Carin Lewis, PharmD, BCPS, BCOP
Na Li, PharmD, PhD, BCOP
Andrea Lippucci, PharmD, BCOP, BCPS
Robert Luschen, PharmD, BCOP
Kathleen Lynch, PharmD, BCOP, BCPS
Jonathan Malara, PharmD, BCOP
Nathan Martens, PharmD, BCOP, CPP
William McSkimming, BSPharm, PharmD, BCOP
Kristin Melathe, PharmD, BCOP
Samantha Meyer, PharmD, MS, BCOP
Rachel Milholland, PharmD, BCOP
Andrea Modlin, PharmD, BCOP
Manuel Morgado, PharmD, BCOP
Katlyn Mulhall, PharmD, BCOP
Nour Mustafa, PharmD, BCOP
Cheryl Nacos, PharmD, BCOP
Jennifer Ng, PharmD, BCACP, BCOP
Jennifer Niccolai, PharmD, BCOP
Grace Park, PharmD, BCOP
Jooyoung Park, PharmD, BCOP
Matthew Peery, PharmD, BCOP
Susan Phy, PharmD, BCOP, CPP
Maria Piddoubny, PharmD, BCOP
Rebecca Polens, PharmD, BCOP
John Powell, BSPharm, RPh, BCOP
Mohammed Qawasmi, PharmD
Morgan Randolph, PharmD, BCOP
Heena Rathod, PharmD BCOP
Mohammad Rattu, PharmD, BCGP, BCOP, BCPS
Forrest Ridgway, PharmD, BCOP, BCPS
Teresa Rushing, PharmD, BCOP, BCPS
Manal Saad, PharmD, BCOP
Stephanie Sanders, PharmD, BCCCP, BCOP
Deborah Sarama, PharmD, BCOP
Monica Sawiris, PharmD, BCOP
Kofi Sefah, PharmD, BCOP
Krystal Seigler, PharmD, BCOP, BCPS
Jon Shaffer, PharmD, BCOP
Lina Shao, PharmD, BCOP
Morgan Steiner, PharmD, BCOP
Jessica Streit, PharmD, BCOP
Randolph Sturgill, PharmD, BCOP
Quang Ta, PharmD, APh, BCPS, BCOP
Nhi Ta, PharmD, BCOP
Ming-Hei Tai, PharmD, BCOP
Ashtin Taylor, PharmD, BCOP
Andrea Thomas, PharmD
Sonia Thomas, PharmD, BCOP
Tara Thompson, PharmD, MBA, BCOP,BCPS CSP
Malgorzata Tyszka, BSPharm, BCOP
Christopher Wang, PharmD, BCOP
Chad Weber, PharmD, BCOP
Elizabeth Weddendorf, PharmD, BCOP
Alora Wilson, PharmD, BCOP
Rebecca Worden, PharmD, BCOP
Lily Yan, PharmD, BCOP
Taylor Yasunaga, PharmD, BCOP
David Yee, PharmD, BCOP
Avani Yenamandra, PharmD, BCOP
Ephu Yip, PharmD, BCOP
Carolnn Yong, PharmD, BCOP, BCPS
Aarti Zaver, PharmD, BCOP
Josh Zhang, PharmD, BCOP
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Courtney Cavalieri: Advisory Board – Bristol Myers Squibb, Daiichi Sankyo, Nuvalent
- Lauren Ice: Consultant – Janssen
- Colleen McCabe: Contractor – Bristol Myers Squibb, Immunocore
- Anthony Peissinotti: Consultant – Amgen, Jazz Pharmaceuticals, Servier
- Danielle Roman: Advisory Board – Daiichi Sankyo, Genentech, Pfizer, Regeneron
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ASHP collaborates with ACCP on oncology pharmacy activities.